Nordea Investment Management AB reduced its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 5.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 218,134 shares of the conglomerate’s stock after selling 12,187 shares during the period. Nordea Investment Management AB’s holdings in Danaher were worth $52,562,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. AM Investment Strategies LLC boosted its holdings in Danaher by 1.5% in the first quarter. AM Investment Strategies LLC now owns 2,728 shares of the conglomerate’s stock valued at $687,000 after acquiring an additional 41 shares during the last quarter. M&R Capital Management Inc. boosted its holdings in Danaher by 0.5% in the first quarter. M&R Capital Management Inc. now owns 9,011 shares of the conglomerate’s stock valued at $2,271,000 after acquiring an additional 42 shares during the last quarter. Silver Oak Securities Incorporated boosted its holdings in Danaher by 4.3% in the first quarter. Silver Oak Securities Incorporated now owns 1,013 shares of the conglomerate’s stock valued at $255,000 after acquiring an additional 42 shares during the last quarter. Bank Pictet & Cie Asia Ltd. boosted its holdings in Danaher by 1.9% in the fourth quarter. Bank Pictet & Cie Asia Ltd. now owns 2,396 shares of the conglomerate’s stock valued at $636,000 after acquiring an additional 44 shares during the last quarter. Finally, Lathrop Investment Management Corp boosted its holdings in Danaher by 2.2% in the first quarter. Lathrop Investment Management Corp now owns 2,050 shares of the conglomerate’s stock valued at $517,000 after acquiring an additional 45 shares during the last quarter. 76.71% of the stock is currently owned by institutional investors.
Danaher Trading Up 0.7 %
NYSE DHR opened at $255.25 on Friday. The firm has a market capitalization of $188.46 billion, a P/E ratio of 29.96, a PEG ratio of 2.72 and a beta of 0.80. The business has a fifty day simple moving average of $253.41 and a 200 day simple moving average of $245.09. Danaher Co. has a 12 month low of $221.22 and a 12 month high of $283.63. The company has a current ratio of 2.08, a quick ratio of 1.70 and a debt-to-equity ratio of 0.35.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Tuesday, July 25th. The conglomerate reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.04. The business had revenue of $7.16 billion during the quarter, compared to analyst estimates of $7.12 billion. Danaher had a return on equity of 15.03% and a net margin of 20.95%. Danaher’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.76 EPS. On average, analysts predict that Danaher Co. will post 8.84 EPS for the current fiscal year.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Thursday, October 12th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Wednesday, October 11th. Danaher’s dividend payout ratio is presently 12.68%.
Wall Street Analyst Weigh In
Several brokerages recently commented on DHR. Stifel Nicolaus reduced their target price on Danaher from $250.00 to $240.00 and set a “hold” rating on the stock in a report on Wednesday, July 26th. StockNews.com assumed coverage on Danaher in a report on Tuesday, September 12th. They set a “hold” rating on the stock. Barclays increased their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Tuesday, July 25th. Royal Bank of Canada increased their price target on Danaher from $260.00 to $292.00 in a report on Wednesday, July 26th. Finally, Bank of America increased their price target on Danaher from $250.00 to $280.00 in a report on Wednesday, July 26th. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $289.79.
View Our Latest Report on Danaher
Insider Activity
In other news, EVP Joakim Weidemanis sold 22,439 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $263.42, for a total transaction of $5,910,881.38. Following the completion of the sale, the executive vice president now directly owns 88,689 shares of the company’s stock, valued at approximately $23,362,456.38. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, SVP Daniel Raskas sold 11,213 shares of the stock in a transaction on Friday, July 28th. The stock was sold at an average price of $260.65, for a total transaction of $2,922,668.45. Following the completion of the transaction, the senior vice president now owns 38,288 shares in the company, valued at approximately $9,979,767.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joakim Weidemanis sold 22,439 shares of the stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $263.42, for a total value of $5,910,881.38. Following the transaction, the executive vice president now owns 88,689 shares of the company’s stock, valued at approximately $23,362,456.38. The disclosure for this sale can be found here. Insiders sold a total of 47,922 shares of company stock valued at $12,552,233 in the last ninety days. 11.10% of the stock is currently owned by insiders.
Danaher Company Profile
(Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Danaher wasn’t on the list.
While Danaher currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
![Beginner's Guide to Pot Stock Investing Cover](https://www.marketbeat.com/logos/premium-reports/small_20230912093357_reportpreview2023-09-pot-investing-cover.png)
Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise.
Get This Free Report